BACKGROUND: Central nervous system (CNS) atypical teratoid/rhabdoid tumors (AT/RT) are aggressive tumors usually diagnosed in young children and characterized by SMARCB1 (INI1, hSNF5) gene abnormalities. Despite initial chemo-radiation responsiveness, most children die of progressive disease (PD). Little data regarding familial AT/RT clinical course exist. This study described and compared familial (F) versus sporadic (S) AT/RT and elucidated SMARCB1 mutations and inheritance patterns. METHODS: A retrospective chart review, pedigree, and SMARCB1 analysis were done. RESULTS: Between January 1989 and June 2009, 20 children with CNS AT/RT were diagnosed, 8-S and 12-F. Median age at diagnosis (months) of S and F patient were: 13 and 4.8, respectively. Median survival (months) was S-21, F4.5, and 8-all. Pedigree analyses showed unaffected parent carriers with multiple affected offspring. CONCLUSIONS: Children with F-AT/RT are younger, have more extensive disease, and are more likely to die from PD than children with S-AT/RT. Surgery, radiation, and chemotherapy were important in achieving long-term survival. Pedigree analysis supports autosomal dominant inheritance pattern with incomplete penetrance. Germline SMARCB1 mutation analysis is important in all patients diagnosed with AT/RT to (1) determine actual incidence of F-AT/RT, (2) determine penetrance of predisposing mutations, (3) provide appropriate genetic counseling, and (4) establish surveillance screening guidelines.
BACKGROUND: Central nervous system (CNS) atypical teratoid/rhabdoid tumors (AT/RT) are aggressive tumors usually diagnosed in young children and characterized by SMARCB1 (INI1, hSNF5) gene abnormalities. Despite initial chemo-radiation responsiveness, most children die of progressive disease (PD). Little data regarding familial AT/RT clinical course exist. This study described and compared familial (F) versus sporadic (S) AT/RT and elucidated SMARCB1 mutations and inheritance patterns. METHODS: A retrospective chart review, pedigree, and SMARCB1 analysis were done. RESULTS: Between January 1989 and June 2009, 20 children with CNS AT/RT were diagnosed, 8-S and 12-F. Median age at diagnosis (months) of S and F patient were: 13 and 4.8, respectively. Median survival (months) was S-21, F4.5, and 8-all. Pedigree analyses showed unaffected parent carriers with multiple affected offspring. CONCLUSIONS:Children with F-AT/RT are younger, have more extensive disease, and are more likely to die from PD than children with S-AT/RT. Surgery, radiation, and chemotherapy were important in achieving long-term survival. Pedigree analysis supports autosomal dominant inheritance pattern with incomplete penetrance. Germline SMARCB1 mutation analysis is important in all patients diagnosed with AT/RT to (1) determine actual incidence of F-AT/RT, (2) determine penetrance of predisposing mutations, (3) provide appropriate genetic counseling, and (4) establish surveillance screening guidelines.
Authors: N Sévenet; A Lellouch-Tubiana; D Schofield; K Hoang-Xuan; M Gessler; D Birnbaum; C Jeanpierre; A Jouvet; O Delattre Journal: Hum Mol Genet Date: 1999-12 Impact factor: 6.150
Authors: Jack Raisanen; Jaclyn A Biegel; Kimmo J Hatanpaa; Alexander Judkins; Charles L White; Arie Perry Journal: Brain Pathol Date: 2005-01 Impact factor: 6.508
Authors: Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith Journal: J Pediatr Hematol Oncol Date: 2002 Jun-Jul Impact factor: 1.289
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962
Authors: Jodi M Carter; Carolyn O'Hara; George Dundas; Dawna Gilchrist; Mark S Collins; Katherine Eaton; Alexander R Judkins; Jaclyn A Biegel; Andrew L Folpe Journal: Am J Surg Pathol Date: 2012-01 Impact factor: 6.394
Authors: Diane K Birks; Andrew M Donson; Purvi R Patel; Christopher Dunham; Andrea Muscat; Elizabeth M Algar; David M Ashley; B K Kleinschmidt-Demasters; Rajeev Vibhakar; Michael H Handler; Nicholas K Foreman Journal: Neuro Oncol Date: 2011-09-23 Impact factor: 12.300
Authors: Sriram Venneti; Paul Le; Daniel Martinez; Katherine W Eaton; Nikhil Shyam; Kelly L Jordan-Sciutto; Bruce Pawel; Jaclyn A Biegel; Alexander R Judkins Journal: J Neuropathol Exp Neurol Date: 2011-07 Impact factor: 3.685
Authors: Mark W Kieran; Charles W M Roberts; Susan N Chi; Keith L Ligon; Benjamin E Rich; Laura E Macconaill; Levi A Garraway; Jaclyn A Biegel Journal: Pediatr Blood Cancer Date: 2012-09-19 Impact factor: 3.167